toggle visibility Search & Display Options

Select All    Deselect All
 |   | 
  Record Links
Author Shaw, D.E.; Sousa, A.R.; Fowler, S.J.; Fleming, L.J.; Roberts, G.; Corfield, J.; Pandis, I.; Bansal, A.T.; Bel, E.H.; Auffray, C.; Compton, C.H.; Bisgaard, H.; Bucchioni, E.; Caruso, M.; Chanez, P.; Dahlen, B.; Dahlen, S.-E.; Dyson, K.; Frey, U.; Geiser, T.; Gerhardsson de Verdier, M.; Gibeon, D.; Guo, Y.-K.; Hashimoto, S.; Hedlin, G.; Jeyasingham, E.; Hekking, P.-P.W.; Higenbottam, T.; Horvath, I.; Knox, A.J.; Krug, N.; Erpenbeck, V.J.; Larsson, L.X.; Lazarinis, N.; Matthews, J.G.; Middelveld, R.; Montuschi, P.; Musial, J.; Myles, D.; Pahus, L.; Sandstrom, T.; Seibold, W.; Singer, F.; Strandberg, K.; Vestbo, J.; Vissing, N.; von Garnier, C.; Adcock, I.M.; Wagers, S.; Rowe, A.; Howarth, P.; Wagener, A.H.; Djukanovic, R.; Sterk, P.J.; Chung, K.F. url  doi
  Title Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort Type Journal Article
  Year (down) 2015 Publication The European Respiratory Journal Abbreviated Journal Eur Respir J  
  Volume 46 Issue 5 Pages 1308-1321  
  Abstract U-BIOPRED is a European Union consortium of 20 academic institutions, 11 pharmaceutical companies and six patient organisations with the objective of improving the understanding of asthma disease mechanisms using a systems biology approach.This cross-sectional assessment of adults with severe asthma, mild/moderate asthma and healthy controls from 11 European countries consisted of analyses of patient-reported outcomes, lung function, blood and airway inflammatory measurements.Patients with severe asthma (nonsmokers, n=311; smokers/ex-smokers, n=110) had more symptoms and exacerbations compared to patients with mild/moderate disease (n=88) (2.5 exacerbations versus 0.4 in the preceding 12 months; p<0.001), with worse quality of life, and higher levels of anxiety and depression. They also had a higher incidence of nasal polyps and gastro-oesophageal reflux with lower lung function. Sputum eosinophil count was higher in severe asthma compared to mild/moderate asthma (median count 2.99% versus 1.05%; p=0.004) despite treatment with higher doses of inhaled and/or oral corticosteroids.Consistent with other severe asthma cohorts, U-BIOPRED is characterised by poor symptom control, increased comorbidity and airway inflammation, despite high levels of treatment. It is well suited to identify asthma phenotypes using the array of “omic” datasets that are at the core of this systems medicine approach.  
  Address National Heart and Lung Institute, Imperial College, London, UK Biomedical Research Unit, Royal Brompton & Harefield NHS Trust, London, UK Joint last authors  
  Corporate Author U-BIOPRED Study Group Thesis  
  Impact Factor 07,636 First Author Shaw, D.E. Editor  
  Language English Summary Language Original Title  
  Series Editor Series Title Abbreviated Series Title  
  Series Volume Series Issue Senior Author Chung, K.F.  
  ISSN 0903-1936 ISBN Medium  
  Area Expedition Conference  
  Notes PMID:26357963 Approved no  
  Call Number Serial 19  
Permanent link to this record
Select All    Deselect All
 |   | 

Save Citations:
Export Records: